StefanoRTarantoloMDFACP

Oncology • Omaha, NE

Hematologic Oncology

Physician

Join to view full profile

Dr. Tarantolo is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Tarantolo's full profile

Already have an account?

Office
8303 Dodge St
Suite 250
Omaha, NE 68114
Phone+1 402-354-8124

Fax+1 402-354-5872

Education & Training

Rutgers Health/Robert Wood Johnson Medical SchoolFellowship, Hematology and Medical Oncology, 1988 - 1991
Jersey Shore University Medical CenterResidency, Internal Medicine, 1985 - 1988
St. George's University School of MedicineClass of 1985

Certifications & Licensure

NE State Medical License 1992 - 2026
NJ State Medical License 1986 - 1993
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Meaningful Use Stage 1 Certification Centers for Medicare & Medicaid Services, 2012
Most Compassionate Doctor American Registry

Clinical Trials

Study to Evaluate Efficacy, Safety, Tolerability, and Pharmacodynamics of Entospletinib in Adults With Relapsed or Refractory Hematologic Malignancies Start of enrollment: 2013 Mar 14
Terminated
Phase 2
Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma
No longer available
A Study Of TAK-981 Given With Monoclonal Antibodies (mAbs) In Adults With Relapsed or Refractory Multiple Myeloma (RRMM) Start of enrollment: 2021 Apr 20
Terminated
Phase 1, Phase 2
Roles: Principal Investigator
The OPAL Study: AVM0703 for Treatment of Lymphoid Malignancies Start of enrollment: 2020 Nov 06
Recruiting
Phase 1, Phase 2
Roles: Contact, Principal Investigator
Join now to see all

Publications & Presentations

PubMed

2 citations
Daratumumab, carfilzomib, and dexamethasone in relapsed or refractory myeloma: final analysis of PLEIADES and EQUULEUS.
Philippe Moreau, Ajai Chari, Albert Oriol, Joaquin Martinez-Lopez, Mathias Haenel
Blood Cancer Journal. 2023-03-07
163 citations
Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial
Saad Z. Usmani, Fredrik Schjesvold, Albert Oriol, Lionel Karlin, Michele Cavo
The Lancet. Haematology. 2019-09-01
173 citations
Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
Maria-Victoria Mateos, Hilary Blacklock, Fredrik Schjesvold, Albert Oriol, David Simpson
The Lancet. Haematology. 2019-07-18

Abstracts/Posters

A Phase 2 Study to Assess the Feasibility and Tolerance of the Combination of Elotuzumab, Lenalidomide, and Dexamethasone (ERd) in the Induction, Consolidation, and Ma...
Stefano R. Tarantolo, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

Curis Inc. (NASDAQ: CRIS) Doses First Subject in the Combination Therapy Study of CA-4948 in AML and MDSNovember 19th, 2021
Curis Inc. (NASDAQ: CRIS) Doses First Subject in the Combination Therapy Study of CA-4948 in AML and MDSNovember 19th, 2021
Finding Inner Peace Through Inner BeautyMay 21st, 2019
Join now to see all